United States

Analyst Research Report Snapshot


WhanIn Pharmaceutical Co., Ltd.






11 May 2015





Companies referenced:

Available for Immediate Download

WhanIn Pharmaceutical Co., Ltd. - Company Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, product and service offerings, and corporate actions, providing a 360° view of the company. Features: - Detailed information on WhanIn Pharmaceutical Co., Ltd. required for business and competitor intelligence needs - Intelligence on WhanIn Pharmaceutical Co., Ltd.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about WhanIn Pharmaceutical Co., Ltd., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: WhanIn Pharmaceutical (WhanIn) is engaged in the development, manufacturing, marketing and sale of therapeutic products. The company offers therapeutic products in categories, including anti-asthmatics, antidepressants, antipsychotics, anxiolytics and hypnotics, antiepileptic, ADHD (attention deficit and hyperactivity disorder) agents, alcoholism treatment, nootropics, anti-Parkinson drugs, anti-dementia drugs, gastrointestinal drugs, cardiovascular drugs, osteoporosis treatment drugs, immune-stimulating agents, anti-inflammatory analgesics and others, erectile dysfunction treatment, antibiotics, multi-vitamins, anti-hemorrhoids, anti-diabetic agents, respiratory drugs, antifungals, antihistamines, dermatological, and antivirals. WhanIn primarily operates in South Korea, where it is headquartered in Seoul and employs around 410 people. The company recorded revenues of KRW104,479.9 million (approximately $96.1 million) in the fiscal year ended December 2013, a decrease of 2.6% compared to 2012. The company's operating profit was KRW20,149.4 million (approximately $18.5 million) in fiscal 2013, an increase of 10.2% over 2012. Its net profit was KRW14,580.1 million (approximately $13.4 million) in fiscal 2013, a decrease of 7.7% compared to 2012. Reasons to Purchase: - Gain understanding of WhanIn Pharmaceutical Co., Ltd. the company and its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess WhanIn Pharmaceutical Co., Ltd. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on WhanIn Pharmaceutical Co., Ltd. your competitors' business structure, strategy and prospects

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.